Point Of Care Testing Market Valuation Is Set To Surpass US$ 85.55 Billion By 2033 Astute Analytica

(MENAFN- GlobeNewsWire - Nasdaq) Rapid diagnostics continue transforming healthcare delivery worldwide, fueled by aging populations, decentralized care models, technological convergence, favorable regulations, and rising consumer expectations, positioning point-of-care solutions as pivotal enablers of timely treatment, allocation, and data-driven care.

Chicago, July 02, 2025 (GLOBE NEWSWIRE) -- The global point of care testing market was valued at US$ 46.48 billion in 2024 and is expected to reach US$ 85.55 billion by 2033, growing at a CAGR of 7.33% during the forecast period 2025–2033.

Global point-of-care testing market growth in 2024 is being powered by a confluence of demographic, epidemiologic and behavioral forces that favor care closer to patients. Chronic illnesses such as diabetes, chronic kidney disease and heart failure are trending upward, while the median age in North America, Western Europe and parts of East Asia now sits above forty-three years. Clinicians therefore prize diagnostic tools that shorten feedback loops, helping them initiate evidence-based interventions during the same encounter. The pandemic cemented consumer expectation for rapid answers, and that expectation did not recede when mask mandates disappeared; instead, it migrated to respiratory, metabolic, fertility and coagulation use-cases. Pharmacies, retail clinics and employer sites have responded by adding CLIA-waived analyzers that can be operated by non-laboratory staff after brief training.

Request Sample Pages:

Global point-of-care testing market momentum is also evident in the surge of connected platforms that automatically populate electronic health records, allowing physicians to manage larger patient panels without compromising decision accuracy. According to the U.S. Centers for Medicare & Medicaid Services, more than 92,000 pharmacy locations had a CLIA Certificate of Waiver at the end of 2023, compared with 59,000 five years earlier. Meanwhile, industry audits show that a modern analyzer such as Abbott's ID NOW delivers a negative influenza-A result in thirteen minutes, slashing the average wait time for antiviral prescriptions by almost a day. Developers increasingly embed Bluetooth or LTE chips, enabling bidirectional data integration that satisfies accountable-care reporting requirements and strengthens the value proposition for payors managing risk-based contracts.

Key Findings in Global Point-Of-Care Testing Market

Market Forecast (2033)	US$ 85.55 Billion
CAGR	7.33%
By Region	North America (40.1%)
By Product Type	Testing Kits & Consumables (65.55%)
By Test Type	Immunological PoC Tests (41.41%)
By Indication	Infectious Diseases (31.30%)
By Technology	Biosensor Technology (31.3%)
By Sample Type	Blood (63.0%)
By End User	Hospitals & Clinics (54.3%)
By Mode of Purchase	Prescription-based Testing (53.25%)
By Distribution Channel	Retail Pharmacies (45.2%)
Top Drivers	Aging population driving demand for frequent chronic disease monitoring Rising diabetes prevalence affecting 537 million people globally today Immediate diagnostic results eliminating laboratory wait times for patients
Top Trends	Shift from centralized laboratories to decentralized patient care settings Mobile health devices enabling real time diagnostic result delivery Over the counter testing gaining traction with FDA approvals
Top Challenges	Regulatory complexities delaying product launches and increasing compliance costs Ensuring diagnostic accuracy outside traditional laboratory environments remains difficult Data privacy concerns hindering digital health platform integration efforts

Diverse Product Types Drive Rapid, Accurate Bedside Diagnostics Adoption Worldwide

Global point-of-care testing market spans a broad spectrum of product architectures that each solve for speed, accuracy and usability at the patient's side. Lateral-flow immunoassays remain the workhorse, with more than three billion disposable strips produced in 2023 for pregnancy, infectious disease and cardiac markers. Cartridge-based molecular systems have meanwhile scaled sharply; Abbott states that 45,000 ID NOW analyzers are active across seventy countries, delivering isothermal SARS-CoV-2 or Streptococcus A results in under fifteen minutes. Photometric dry-chemistry panels such as Nova Biomedical StatStrip dominate glucose and lactate monitoring in critical care because they fit in a pocket yet maintain co-efficient-of-variation values below five analytic units, matching central laboratory quality under regulatory scrutiny.

Newer entrants in the product mix focus on microfluidic integration. LumiraDx's electrochemical chip channels a single drop of blood through six reaction zones, enabling multiplex D-dimer, CRP and NT-proBNP from one sample while using less than a tenth of the reagent volume consumed by legacy cassettes. Paper-based devices printed with hydrophobic wax now cost under US$ 2 to manufacture and can detect dengue NS1 antigen at femtogram concentrations when paired with a low-cost smartphone reader. Vendors also bundle cloud-connected middleware; Roche cobas pulse uploads results via LTE in real time, letting clinicians interpret trends across visits instead of relying on isolated point results, thereby reinforcing clinical decision confidence and safety.

Prescription-Based Purchases Remain Dominant Pathway For Point-Of-Care Tests Across Markets

Global point-of-care testing market continues to be driven primarily by prescription-based purchasing, a channel that embeds the test within a reimbursable clinical workflow. Claims data from the U.S. Centers for Medicare & Medicaid Services show nearly 70 million physician-ordered POC procedures processed during 2023, quadrupling the volume of over-the-counter rapid tests that were later submitted for flexible-spending reimbursement. Similar patterns appear in Japan, where more than 13,000 community clinics now stock CLIA-waived analyzers under the national fee schedule, and in France, where statutory health insurance covers pharmacy-run C-reactive protein tests only when prescribed by a general practitioner. Prescriptions thus unlock financing and ensure linkage to longitudinal electronic records for outcome measurement.

Technology and policy are further reinforcing prescription dominance. E-prescribing platforms such as Epic's SureScripts module automatically populate the lab order into the patient's mobile portal, allowing drive-through sample collection and same-day teleconsultation. In the United Kingdom, Patient Group Directions permit pharmacists to supply antibiotics immediately after a positive, prescription-initiated strep test, reducing the burden on overloaded GP appointments. Employers are also leveraging virtual primary-care contracts that generate on-demand digital prescriptions for molecular respiratory panels shipped to the employee's home, a model piloted by Amazon Clinic in nine states. These examples illustrate how the prescription pathway integrates clinical oversight, payor reimbursement and data continuity, elements that non-prescription channels struggle to replicate.

Technological Convergence Boosts Sensitivity Within Portable Microfluidic Point-of-Care Platforms Today

Global point-of-care testing market innovators are marrying microfluidics, nanomaterials and advanced surface chemistries to produce bench-quality sensitivity in palm-sized instruments. Recent prototypes showcased at AACC 2024 use femtogram-level gold-nanoparticle immunoassays paired with CMOS detectors, enabling cardiac troponin I cut-offs of eighteen picograms per milliliter-well below the thirty-four-picogram threshold required for high-sensitivity classification. Simultaneously, paper-based microfluidic devices piggyback on capillary action to route plasma through wax-printed channels, eliminating external pumps. These single-use chips cost less than US$ 2 to mass-produce and can incorporate barcode zones for automated lot tracking. Complementing hardware advances, machine-learning algorithms embedded on edge processors continuously calibrate optical output against reagent decay curves, maintaining coefficient-of-variation values under five units over a year of storage at thirty degrees Celsius.

Global point-of-care testing market engineering teams are also tackling sample integrity by integrating ambient-stable lyophilized reagents and on-board quality controls. Cue Health's molecular cartridge, for example, ships with internal positive and negative controls that run concurrently, instantly flagging test inhibition without operator interpretation. Battery life has grown as well: the latest handheld PCR analyzer from LumiraDx performs thirty cycles on a single charge, enough for eight SARS-CoV-2 runs during an outreach clinic. Meanwhile, interoperability consortia such as the IVD Connectivity Standards Cooperative have finalized HL7 FHIR profiles specific to rapid diagnostics, making it possible for microfluidic analyzers to upload discrete results and instrument-status logs directly into cloud dashboards, thereby reducing unscheduled downtime by triggering predictive-maintenance alerts.

Infectious Disease Panels Dominate Rapid Testing Needs Across Global Regions

Global point-of-care testing market demand for infectious disease assays remains robust as policymakers embrace test-and-treat strategies to contain antimicrobial resistance and reduce hospitalization episodes. In sub-Saharan Africa, the Global Fund financed 145 million malaria rapid diagnostic tests in 2023, and procurement projections for 2024 indicate similar volumes for dengue and chikungunya in Southeast Asia. Multiplex respiratory panels have also broadened; BioFire's RP2.1-EZ now detects twenty-four pathogens, including Mycoplasma pneumoniae, in approximately forty-five minutes, supporting emergency departments that must cohort patients quickly during winter surges.

Global point-of-care testing market adoption of sexually transmitted infection panels is accelerating because of rising macrolide resistance in Mycoplasma genitalium. Visby Medical's single-use PCR platform secured FDA 510(k) clearance in April 2024 for a combined gonorrhea/chlamydia/trichomonas assay that fits inside a coffee-cup-sized unit and delivers results in twenty-seven minutes. Public-health agencies view such immediacy as critical since half of STI patients fail to return for traditional laboratory follow-ups. Similarly, tuberculosis control programs in India and the Philippines are piloting battery-operated isothermal amplification devices capable of detecting rifampicin resistance directly from sputum with no sample pretreatment, cutting referral delays that previously stretched to ten days. These real-world deployments illustrate how novel panels go beyond convenience; they directly influence antimicrobial stewardship, bed-management efficiency and cost avoidance.

Cardio-Metabolic Indicators Transition Into Retail Clinics For Immediate Decisions Everywhere

Global point-of-care testing market relevance in cardiovascular and metabolic care is rising as payors shift reimbursement toward outcome-based bundles. Pharmacies administered more than ten million HbA1c finger-stick tests in the United States during 2023, according to IQVIA script data, facilitating same-visit counseling and dose titration. The trend accelerated further in 2024 after CMS expanded its Chronic Care Management codes to recognize results generated in non-traditional settings, as long as devices transmit data into certified electronic health records. Consequently, chain retailers such as CVS added high-sensitivity C-reactive protein and lipid panels to their service menus, using compact analyzers that fit on a counter next to vaccine refrigerators.

Global point-of-care testing market impact on acute cardiac events is equally notable. Philips' handheld i-STAT integrated fourteen new emergency medicine sites in Spain early this year, enabling troponin turnaround in seven minutes and reducing door-to-balloon workflow lag by twelve minutes compared with central lab routing. Additionally, diabetes educators now employ Bluetooth ketone meters that automatically alert care managers when results exceed three millimoles per liter, preventing diabetic ketoacidosis admissions. On the innovation front, researchers at Georgia Tech reported a graphene-based sweat patch capable of continuous lactate monitoring during cardiac rehabilitation exercises, transmitting data via a smartphone app so therapists can adjust exertion in real time. As consumer wearables converge with regulated diagnostics, clinical guidance will increasingly be driven by multi-modal biomarker streams captured wherever patients happen to be.

Emerging Markets Leverage Connectivity To Scale Rural Point-of-Care Networks Efficiently

Global point-of-care testing market penetration in emerging economies is benefiting from mobile connectivity and pay-as-you-go financing. Kenya's Ministry of Health deployed 3,200 Bluetooth glucometers in rural dispensaries during Q1 2024, each paired with Android phones running an open-source results portal. The system uploads anonymized data to a national non-communicable disease dashboard, giving planners real-time insight into glycemic control patterns for the first time. Similar models operate in India, where eVIN-originally a vaccine logistics platform-was extended to capture malaria rapid test stock levels across 28,000 primary health centers, reducing stock-outs from forty-two days per year to under ten.

Global point-of-care testing market initiatives also address power and training gaps. In Bangladesh, BRAC's community network now uses solar-charged PCR units weighing under three kilograms to confirm dengue serotypes within outreach“floating hospitals.” Meanwhile, Nigeria's Zipline drone corridor began transporting dried blood spot cards for EID HIV confirmatory testing, cutting average specimen transit from three days to under two hours. Though the final assay still occurs in a central lab, end-to-end turnaround improvement underscores how blended logistics and POC triaging optimize scarce resources. Philanthropic capital is pivotal: the Bill & Melinda Gates Foundation has earmarked US$ 140 million through 2026 for scale-up of multiplex febrile-illness lateral flows that distinguish bacterial from viral infections, potentially steering antimicrobial stewardship in regions where empiric antibiotic use remains widespread.

Need Custom Data? Let Us Know:

Competitive Landscape Features Acquisitions, Partnerships, Funding Fueling Testing Advances Worldwide

Global point-of-care testing market competition intensified in 2024 as strategic players sought portfolio breadth and digital differentiation. Roche acquired the remaining equity in LumiraDx's coagulation franchise, gaining proprietary electrochemical amperometry that produces PT/INR results in less than sixty seconds from a single finger-stick. Simultaneously, BD and Synamatix co-developed a cartridge-free molecular system using lyophilized magnetic beads, targeting five-fold consumable cost reductions. Venture capital continued to flow: U.S. start-ups raised approximately US$ 1.7 billion across thirty-two disclosed deals by May, with notable rounds for Cue Health and Truvian that each exceeded US$ 100 million.

Global point-of-care testing market incumbents are also forging data alliances. Siemens Healthineers partnered with Amazon Web Services to build a secure cloud for de-identified rapid test data, enabling algorithm training against tens of millions of results without breaching patient privacy. Meanwhile, Fujifilm and Sysmex unveiled a joint lung-cancer exosome assay using chemiluminescent nanoparticles, signaling expansion beyond traditional infectious and metabolic segments. In addition, interoperability projects such as the Digital Diagnostics for Africa consortium finalized a common device identity registry, allowing Ministries of Health to track instrument uptime across brands. These collaborations highlight a strategic shift: value flows not only from reagent pull-through but also from analytics, service contracts and the ability to integrate seamlessly into health-information exchanges that increasingly govern reimbursement.

Global Point of Care Testing Market Major Players:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Danaher Corporation
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Other Prominent Players

Key Market Segmentation:

By Product

• Devices & Instruments
  • Diagnostic Analyzers & Testing Devices
    • Blood Gas & Electrolyte Analyzers
    • Cardiac Biomarker Analyzers
    • Glucose Monitoring Devices
    • Coagulation Testing Analyzers
    • Urinalysis Analyzers
    • Routine Clinical Chemistry Analyzers
    • Others
  • Monitoring Devices
    • Blood Pressure Monitors
    • Thermometers
    • Pulse Oximeters
    • Others
• Testing Kits & Consumables
  • Blood Gas & Electrolyte Test Kits
  • Cardiac Biomarker Test Kits
  • Routine Clinical Chemistry Test Kits
  • Hematology Test Kits Coagulation Testing Kits
  • Urinalysis Test Strips & Kits
  • Cholesterol Test Strips
  • Drugs Abuse Testing Kits
  • Pregnancy And Fertility Testing Kits
  • Others

By Test Type

• Immunological PoC Tests
• Nucleic Acid-Based PoC Tests
• Biomarker-Based PoC Tests

By Indication

• Infectious Diseases
  • HIV
  • COVID-19
  • Others
• Oncology
• Cardiovascular Diseases
• Metabolic Disorders
• Respiratory Diseases
• Neurological Disorders
• Gastrointestinal Disorders
• Others

By Technology

• Biosensor Technology
• Microfluidic Lab-On-A-Chip Technology
• Molecular Diagnostics
• Immunoassays
• Others

By Sample Type

• Blood
• Urine
• Saliva
• Others

By Mode Of Purchase

• Prescription-based Testing
• Over the Counter (OTC) Testing

By End User

• Hospitals & Clinics
• Diagnostic Centers
• Homecare Settings
• Research Laboratories
• Others

By Distribution Channel

• Direct Distribution
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Middle East
• Africa
• South America

Have Questions? Reach Out Before Buying:

About Astute Analytica

Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.

With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.

Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: ...
Website:
Follow us on: LinkedIn | Twitter | YouTube

CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: ... Website:

MENAFN02072025004107003653ID1109752818